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Abstract 
Imatinib treatment in metastatic or inoperable gastrointestinal stromal tumours (GIST) has shifted the paradigm of treatment of this 
disease. Successful clinical trials of imatinib led to rapid regulatory approval and, in England and Wales, National Institute for Health and 
Clinical Excellence (NICE) guidance on use of this technology. NICE recommend detailed audit of their guidelines in clinical practice. 
This audit reflects that guidance and was designed to document the use of imatinib in routine clinical practice.  
Methods: We conducted a retrospective audit of patients with GIST treated with imatinib from 1 February 2002 to 31 March 2007. 
Information gathered included patient demographics, disease characteristics and details of treatment administered, treatment response, 
toxicities and follow-up data. The primary objective was to record disease control rate (DCR), defined as a lack of progression on 
computed tomography at three months. Secondary end points of this audit were progression-free and overall survival. These were 
compared with published clinical trial results.  
Results: Thirty-six consecutive patients with a diagnosis of GIST treated with imatinib were identified. Median age of patients was 70.1 
years. At the time of analysis, patients have been followed up for a median of 41.6 months. In total, patients were treated for a median of 
15.8 months. Treatment was generally well tolerated with a small percentage of patients experiencing grade 3/4 toxicities. Disease 
control was observed in 30 patients (DCR, 83.3%, 95% CI 67.2–93.6, intention to treat analysis). The median progression free survival 
(PFS) in this cohort was 23.7 months (95% CI 12.9–34.4); while the median overall survival was 39.7 months (95% CI 22.8–56.5).  
Conclusion: Our data demonstrated that the treatment of unselected GIST patients within the NICE guidance compares favourably to 
previously published data of randomized registration studies of imatinib. Of note, the median age of this cohort is some ten years older 
than that reported in the trials. Imatinib was well tolerated with acceptable treatment-related adverse events. 
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Introduction 
The term gastrointestinal stromal tumours (GIST) was first 
coined by Mazur and Clark to describe gastrointestinal non-
epithelial neoplasms that had neither smooth muscle nor 
Schwann-cell features [1]. They are thought to be derived from 
the interstitial cells of Cajal, which are the pacemaker cells of 
gastrointestinal tract [2]. 
Although GISTs are the commonest mesenchymal tumour of 
the gastrointestinal tract, they are relatively rare. Its exact 
incidence remains unknown, but is estimated at 14.5 cases per 
million in Sweden [3]. They commonly occur in people above 
the age of 50, with almost a similar distribution across the male 
and female gender [3,4]. GISTs are most commonly found in 
the stomach and small bowel, but they can occur in all other 
parts of the gastrointestinal tract as well as the abdominal and 
pelvic cavity. Liver and peritoneum are the most common sites 
of metastases [5]. The malignant potential of GIST depends on 
some features of the tumour, mainly size and mitotic rate [6]. 
The larger the size and the higher the mitotic rate, the more 
aggressive behaviour and risk of relapse the GIST will have. 
The location of GIST also has an impact on the outcome, with 
gastric tumours having a better prognosis than the intestinal 
tumours of the same features [7]. 
Definite diagnosis of this tumour requires histological 
confirmation. The landmark feature is the positive staining for 
CD117 receptor, also known as c-kit receptor. It is a trans-
membrane tyrosine kinase receptor for the cytokine stem cell 
factor. The majority of GISTs (circa 85%) expresses this protein. 
GISTs are often also positive for CD34, a cell surface protein 
also found in blood progenitor cells and endothelial cells. Less 
frequently, GIST cells are positive for smooth muscle actin 
(SMA), and they are rarely positive for the marker of cells 
derived from the neural crest (S100) [2,6,8,9]. 
Most GISTs have a gain of function mutation in the KIT proto-
oncogene (cKIT) that translates into a constitutive ligand 
independent activation of the tyrosine kinase receptor [10]. This 
is thought to be the key event in the pathogenesis of GIST [11]. 
However, a minority of GISTs contain mutations in the 
homologous kinase platelet-derived growth factor receptor 
alpha (PDGFR-α) gene [12]. Mutations of these two closely 
related tyrosine kinases are mutually exclusive; with about 85–
90% of GISTs, having a mutation in one of these two kinase 
genes [13]. The remaining GISTs carry the wild KIT gene type. 
To date, there are several mutations identified that have 
therapeutic implications. The most common cKIT mutation, 
exon 11, shows good response to the tyrosine kinase inhibitor 
imatinib and better overall survival (OS) than the less commonly 
occurring exon 9 mutation and the wild type GIST [14]. 
Surgery is the mainstay treatment for small-localized tumours. 
For locally advanced, inoperable or metastatic disease, tyrosine 
kinase inhibitor, imatinib mesylate, is the current worldwide 
standard first line treatment. It represents a revolution in the 
treatment of this notoriously chemotherapy-resistant tumour. 
Historically, the response rate to chemotherapy was very low, 
and the median survival for advanced disease was between 12 
and 24 months [4,5,15]. Several phase 1 and 2 trials 
established the high efficacy and good tolerability of imatinib in 
treatment of GISTs [16-18]. A pivotal randomized trial 
conducted mainly in Europe showed an overall response rate of 
52% and stable disease in 32% of patients [19]. The findings of 
the above trial was confirmed by another large trial, 
demonstrating an overall response rate of 45% while stable 
disease was achieved in 25% of patients [20]. With the use of 
imatinib, the median overall survival has improved dramatically, 
with a median overall survival exceeding 50 months [20,21]. 
The treatment protocol for patients in England and Wales with 
GIST is mandated by the National Institute for Health and 
Clinical Excellence (NICE) guidance (www.nice.org.uk/TA86/ 
guidance). In essence, this guidance recommended: (i) 
treatment with imatinib for patients with unresectable/metastatic 
GIST at 400 mg daily under the supervision of cancer 
specialists with experience in the management of this disease; 
(ii) patients should be assessed on a 12-weekly basis and kept 
in treatment if the disease is responding to treatment, defined 
as stable disease or better; and (iv) patients who have 
progressed on imatinib therapy should have their treatment 
discontinued. NICE also recommended auditing the above 
guidance against local practices. 
Despite the impressive results with imatinib treatment of this 
disease, little is known with regards to its efficacy in day-to-day 
clinical setting. We therefore undertook a retrospective audit of 
consecutive, unselected patients with GISTs who were treated 
with imatinib within the NICE guidance. 
  
Methods 
Patients 
Potential patients were identified from the Northern Cancer 
Network (NCN) soft tissue and bone sarcoma multidisciplinary 
meeting (MDM) registry from 1 February 2002 to 31 March 
2007. The NCN covers a population base of more than two 
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million people and is responsible for oncological care for 
patients from the north-east of England. The NCN soft tissue 
and bone sarcoma MDM comprises dedicated pathologists, 
radiologists, surgeons and oncologists. 
Patients with a histological confirmation of GIST who were 
treated with imatinib were included in this series. We examined 
patient demographics, disease characteristics and details of 
treatment administered. Information on treatment response, 
treatment failure, toxicities and follow-up were also collected. 
Each patient record was examined and data were retrieved for 
the above parameters. This audit was approved by the Caldicott 
Committee of the Newcastle upon Tyne Hospitals NHS 
Foundation Trust, which acts as the custodian of patient records 
and confidentiality at our institution. 
Treatment
Patients were treated as per recommendation of the NICE 
guidelines. All patients were treated with imatinib mesylate, 400 
mg once daily p.o. unless specified otherwise. Patients were 
reviewed weekly for the first four weeks, then monthly for two-
month and three-month visits from thereon. All patients had 
computed tomography (CT) evaluation pre-treatment, with 
three-month CT scans planned throughout treatment duration. 
More recently, a follow-up schedule with fewer visits has also 
been adopted. 
Audit end points
The primary end point of this retrospective audit was visual 
radiographic assessment for response and the clinical 
impression. This was evaluated as disease control rate (DCR), 
defined as a lack of clinically relevant progression on computed 
tomography (CT) at three months post-treatment initiation. We 
chose DCR as our primary end point as it reflects everyday 
clinical practice and it reflects accordance to the NICE 
guidelines. Whilst we also collated data on conventional 
response parameters (complete response (CR), partial 
response (PR), stable disease (SD) and disease progression 
(PD)), we acknowledge the limitations of response assessment, 
using conventional response parameters such as RECIST 
parameters in this disease [22]. 
Secondary end points of this audit included progression-free 
and overall survival. Progression-free survival (PFS) was 
defined as the time from start of imatinib treatment until 
documented progression or death from any cause. Overall 
survival was defined as the time from start of imatinib treatment 
to the time of the last review or death from any cause. Patients 
who were alive on the date of last follow-up were censored on 
both analyses. 
Safety profile
Common toxicity criteria according to the National Cancer 
Institute Grading System (version 3.0) were used in the 
evaluation of treatment toxicity. 
Statistical methods
The Kaplan-Meier method was used to generate estimation of 
progression-free and overall survival [23]. 
  
Results 
Patient characteristics and treatment details
From 1 February 2002 to 31 March 2007, 36 patients with a 
diagnosis of GIST underwent treatment with imatinib within the 
Northern Cancer Network. Baseline characteristics of patients, 
their disease and previous treatment are summarized in Table 
1. At the start of treatment with imatinib, 27 patients (75%) had 
metastatic disease, whilst five patients (13.9%) had locally 
advanced inoperable disease. Four patients (11.1%) were 
treated with imatinib despite having localized disease only as 
they were medically unfit for surgery. 
In total, patients were treated for a median of 15.8 months. Two 
patients started imatinib at 200 mg daily p.o. as a precaution 
against bleeding problems. No patients had a dose of imatinib 
more than 400 mg o.d. Treatment deferral was documented in 
five patients due to toxicity. At the time of analysis, 26 out of 36 
patients have had their imatinib treatment discontinued. Primary 
reason for treatment discontinuation was progressive disease 
(PD) (n=20), followed by treatment toxicity (n=6). All patients 
with progressive disease had their treatment discontinued. 
Treatment response and benefit
Thirty-four patients were evaluable for treatment response. Two 
patients (5.6%) were not evaluable for radiological response 
due to early clinical deterioration. DCR was observed in 30 
patients (83.3 %, 95% CI 67.2–93.6, intention to treat analysis). 
There were no CR, whilst progressive disease was noted in four 
patients (11.1%). Treatment failure denoted by progressive 
disease on radiological assessment or the occurrence of early 
clinical deterioration occurred in six patients (16.7%). 
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Table 1: Patient, disease and previous treatment demographics characteristics of patients, disease and previous treatment 
The median PFS in this cohort was 23.7 months (95% CI 12.9–
34.4), whilst the median OS was 39.7 (95% CI 22.8–56.5). The 
PFS and OS actuarial plot is represented by Figures 1 and 2, 
respectively. 
Toxicity
In general, treatment with imatinib was tolerated well. There 
were no grade 3/4 haematological toxicities necessitating
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Figure 1: Progression-free survival curve—Kaplan-Meier plot for progression-free survival for all patients. 
 
treatment deferral in our series. In 14 patients (38.8%), 
treatment was tolerated with no clinical toxicity. Non-
haematological toxicities, when they occurred, were usually 
mild, with periorbital oedema (n=9), nausea (n=4), diarrhoea 
(n=3) and rash (n=3) being the commonest complain. However, 
a small proportion of patients developed grade 3/4 non-
haematological toxicities and these are documented in Table 2. 
 
Discussion 
The use of imatinib in the management of inoperable and 
metastatic GIST represented a sea change in the management 
of these tumours. For many years, GISTs were not recognized 
as a separate clinical entity from leiomyosarcomas [24], and it 
was only really when the opportunity for targeted therapy using 
imatinib in this disease was mooted that clinicians began to 
treat them as a separate clinical identity from other 
retroperitoneal sarcomas.  
Following on from the success of imatinib in the management of 
chronic myeloid leukaemia [25], the role of this drug in GISTs 
was then established with a series of rapidly accruing phase 1, 
2 and 3 trials conducted in parallel in Europe and North 
America, leading to the rapid licensing of the drug followed by 
approval in the United Kingdom from NICE.  
One of the inevitable consequences of this rapid regulatory 
approval was that clinicians treating the disease knew the 
sometimes dramatic effect of imatinib treatment, but very few 
had experience of using the drug in real life. One distinct clinical 
group, the extreme elderly, who many would have not 
considered clinical trial material and their treatment of GIST 
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Table 2: Grade 3/4 non-haematological toxicities
 
Figure 2: Overall survival curve—Kaplan-Meier plot for overall survival for all patients. 
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patients on imatinib is response assessment. As alluded to 
earlier, we have chosen DCR as the primary end point for 
response evaluation to imatinib as opposed to traditional end 
points such as RECIST as it may be inaccurate in this setting. 
However, at present, the use of positron emission tomography 
imaging is fast becoming the standard modality for response 
evaluation for this disease in many institutions, negating the 
shortcomings of CT response assessment [26,27]. 
The NCN soft tissue and bone sarcoma group took an early 
lead in making imatinib available for patients in the region and 
the contribution of sarcoma, gastrointestinal (both upper and 
lower) and hepatobiliary surgeons to regular meetings along 
with the presence of specialist sarcoma and gastrointestinal 
pathologists, radiologists and oncologists undoubtedly 
contributed to the ability to manage these patients effectively.  
This series represents the results of multi-disciplinary 
management of this group of patients. The management 
guidelines were, essentially, fixed by the NICE guidance on the 
management of GIST, which is applicable locally and has been 
followed closely. This has enabled the generation of detailed 
individual patient data on response and treatment outcome. Our 
response rate (to include patients who had partial response and 
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stable disease), time to progression and overall survival map 
almost exactly onto the published trial data from both the 
EORTC and the American Intergroup studies and show that in a 
multi-disciplinary setting in a UK centre, it is possible to match 
the results of clinical trials in the population as a whole, not just 
in those patients who would be eligible for clinical trials. Our 
results underpin both the efficacy and safety of imatinib 
treatment despite the high median age of patients in the cohort. 
This age distribution makes our experience unique among the 
published series.  
Our unexpected finding of cardiac toxicity in two of the patients 
in the series highlights the importance of continuing pharmaco-
vigilance after product licensing. This was not a finding that was 
expected from the registration studies and may, in part, be a 
reflection of the age group treated. It raises the question of a
need to monitor cardiac function in selected patients although 
our review does not have the power to answer this. 
  
Conclusion 
Our data show that in routine clinical practice based on a 
comprehensive multi-disciplinary team framework, the 
impressive results produced by imatinib in GISTs in the 
randomized pivotal trials can be reproduced. The treatment can 
be delivered safely and the response rates and other clinical 
outcomes map onto the published clinical trial data. This audit 
meets the NICE requirement for practice evaluation and our 
results confirm the appropriateness of the NICE guidance to UK 
practice. 
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